Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECARDO study of docetaxel + carboplatin versus docetaxel in docetaxel-sensitive metastatic hormone-refractory prostate cancer
NL-OMON27233Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in castration-resistant prostate cancer (CRPC) comparing docetaxel + carboplatin with docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2009; status: active, not recruiting.
02
Drugs
docetaxelcarboplatin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON27233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27233.